Dr. Sankhala on the Significance of TRC105/Pazopanib in Angiosarcoma | OncLive

Dr. Sankhala on the Significance of TRC105/Pazopanib in Angiosarcoma

April 10, 2017

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses the significance of the combination of the endoglin antibody TRC105 plus pazopanib (Votrient) in patients with angiosarcoma.

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses the significance of the combination of the endoglin antibody TRC105 plus pazopanib (Votrient) in patients with angiosarcoma.

Angiosarcoma is a challenging subtype of sarcoma that is also very aggressive, Sankhala explains. There are some chemotherapy options used to treat these patients, including paclitaxel and doxorubicin. While patients do respond to the chemotherapy, their disease recurs and progresses quickly, he adds.

With the discovery of TRC105, researchers predict that this will achieve prolonged stabilization of responses in these patients, Sankhala explains.


x